摘要
目的 利用UPLC-Q-Exactive Orbitrap MS技术对二至丸在D-半乳糖模型大鼠体内的成分进行辨识分析,阐明其治疗阿尔茨海默病的药效物质基础。方法 SD大鼠连续4周腹腔注射D-半乳糖构建学习记忆障碍模型,实验前灌胃给予二至丸药液,以空白SD大鼠为对照,采集血浆和脑脊液样品,采用ACQUITY UPLC BEH C色谱柱(2.1 mm×100 mm,1.8 μm),以甲酸-水和0.1%的甲酸-乙腈为流动相,梯度洗脱,流速0.3 mL·min^(-1),进样量5 μL,电喷雾离子源(ESI),正、负离子模式下采集。结果 共鉴定出木犀草素-7-O-葡萄糖苷、大波斯菊苷、木犀草素、芹菜素等25种原形入血成分和木犀草素、红景天苷和蟛蜞菊内酯3种原形入脑成分。结论 初步确定了二至丸的入血入脑成分,它们可能是二至丸治疗阿尔茨海默病的直接作用物质。
Objective To determine the constituents in compound Erzhi pills in D-gal model rats by UPLC-Q-Exactive Orbitrap MS,and briefly clarify the effective substance basis of its medicine for Alzheimer’s disease.Methods SD rats were intraperitoneally injected with D-gal for 4 weeks to establish the learning and memory impairment model.Before the experiment,Erzhi pills were given intragastrically,and blank SD rats were used as controls.The plasma and cerebrospinal fluid samples were collected.The separation were performed on ACQUITY UPLC BEH Ccolumn (2.1 mm×100 mm,1.8 μm).Formic acid-water and 0.1% formic acid-acetonitrile was used as the mobile phase with gradient elution.The flow rate was 0.3 mL·min^(-1) and the injection volume was 5 μL.Electrospray ion source and acquisition in the positive and negative ion modes were used.Results Totally 25 prototypic hematogenous components (such as luteolin-7-O-glucoside,cosmosiin,luteolin and apigenin),and 3 prototypic intracerebral components (luteolin,salidroside and wedelolactone) were identified.Conclusion This experiment preliminarily confirms the blood and brain components of Erzhi pills,which might be the direct acting substances in Erzhi pills for Alzheimer’s disease.
作者
林雪
薛傲
徐艳明
孙琪
徐红丹
薛慧
杨波
张宁
LIN Xue;XUE Ao;XU Yan-ming;SUN Qi;XU Hong-dan;XUE Hui;YANG Bo;ZHANG Ning(School of Pharmacy,Heilongjiang University of Chinese Medicine,Harbin 150040;School of Jiamusi,Heilongjiang University of Chinese Medicine,Jiamusi Heilongjiang 154007)
出处
《中南药学》
CAS
2022年第10期2247-2252,共6页
Central South Pharmacy
基金
国家自然科学基金面上项目(No.82174007)
国家自然科学基金青年科学基金项目(No.82003975)
黑龙江省卫生健康委科研课题(No.2020-303)
黑龙江中医药大学基金项目(No.2018RCD19,No.2018pt04,No.2019BJP01)。
